Cancer statistics, CA Cancer J Clin, vol.63, pp.11-30, 2013. ,
Efficacy and safety of bevacizumab -based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study), Eur J Cancer, vol.49, pp.1236-1281, 2013. ,
Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases, J Clin Oncol, vol.31, pp.1931-1939, 2013. ,
Prognostic and predictive response factors in colorectal cancer patients: between hope and reality, World J Gastroenterol, vol.20, pp.15049-59, 2014. ,
Association of weight change after colorectal cancer diagnosis and outcomes in the Kaiser Permanente northern California population, Cancer Epidemiol Biomark Prev, vol.26, pp.30-37, 2017. ,
Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index, J Clin Oncol, vol.31, pp.1539-1586, 2013. ,
Association of systemic inflammation and sarcopenia with survival in non-metastatic colorectal cancer: results from the C SCANS study, JAMA Oncol, vol.3, p.172319, 2017. ,
Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy, Support Care Cancer, vol.23, pp.687-94, 2015. ,
Influence of body composition profile on outcomes following colorectal cancer surgery, Br J Surg, vol.103, pp.572-80, 2016. ,
A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands, Am J Clin Nutr, vol.89, pp.1173-1182, 2009. ,
Validation of skeletal muscle volume as a nutritional assessment in patients with gastric or colorectal cancer before radical surgery, J Clin Med Res, vol.9, pp.844-59, 2017. ,
Sarcopenia is associated with chemotherapy toxicity in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer, Ann Surg Oncol, vol.23, pp.3891-3899, 2016. ,
Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer, Curr Opin Support Palliat Care, vol.7, pp.383-392, 2013. ,
Drug dose per kilogram lean body mass predicts hematologic toxicity from carboplatin-doublet chemotherapy in advanced non-small-cell lung cancer, Clin Lung Cancer, vol.18, pp.129-165, 2017. ,
Assessment of nutritional status in cancer--the relationship between body composition and pharmacokinetics, Anti Cancer Agents Med Chem, vol.13, pp.1197-203, 2013. ,
Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer, Nutr Cancer, vol.66, pp.583-592, 2014. ,
Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens, Cancer Med, vol.5, pp.607-623, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01881582
Muscle mass at the time of diagnosis of non-metastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: the C-SCANS study, Cancer, vol.123, pp.4868-77, 2017. ,
Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer, J Clin Oncol, vol.34, pp.1339-1383, 2016. ,
Skeletal muscle changes after elective colorectal cancer resection: a longitudinal study, Ann Surg Oncol, vol.23, pp.2539-2586, 2016. ,
Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential?, Am J Clin Nutr, vol.98, pp.1012-1021, 2013. ,
Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo -controlled study, J Clin Oncol, vol.28, pp.1054-60, 2010. ,
Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study, Support Care Cancer, vol.25, pp.3365-73, 2017. ,
Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study, Lancet Oncol, vol.9, pp.629-664, 2008. ,
Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image, J Appl Physiol, vol.9, pp.2333-2341, 1985. ,
A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care, Appl Physiol Nutr Metab, vol.33, pp.997-1006, 2008. ,
Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content, J Appl Physiol, vol.89, pp.104-114, 1985. ,
A note on quantifying follow-up in studies of failure time, Control Clin Trials, vol.17, pp.343-349, 1996. ,
Statistical approaches for evaluating body composition markers in clinical cancer research, Expert Rev Anticancer Ther, vol.17, pp.311-319, 2017. ,
The relationship between tumour stage, systemic inflammation, body composition and survival in patients with colorectal cancer, Clin Nutr, vol.37, pp.1279-85, 2018. ,
Barriers to the interpretation of body composition in colorectal Cancer: a review of the methodological inconsistency and complexity of the CT -defined body habitus, Ann Surg Oncol, vol.25, pp.1381-94, 2018. ,
Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity, Clin Cancer Res, vol.13, pp.3264-3272, 2007. ,
Intramyocellular lipid droplets increase with progression of cachexia in cancer patients, J Cachexia Sarcopenia Muscle, vol.2, pp.111-118, 2011. ,
Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications, Mol Asp Med, vol.34, pp.1-11, 2013. ,
A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab, Med Oncol, vol.29, pp.1005-1014, 2012. ,
Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients, J Cachexia Sarcopenia Muscle, vol.9, pp.909-928, 2018. ,
Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle, J Appl Physiol, vol.107, pp.1935-1977, 1985. ,
Direct effects of doxorubicin on skeletal muscle contribute to fatigue, Br J Cancer, vol.100, pp.311-315, 2009. ,
Voluntary exercise prevents cisplatin-induced muscle wasting during chemotherapy in mice, PLoS One, vol.9, p.109030, 2014. ,
Chemotherapy -related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs, Oncotarget, vol.7, pp.43442-60, 2016. ,
The determinants of reduced dietary intake in hospitalised colorectal cancer patients, Support Care Cancer, vol.26, pp.2039-2086, 2018. ,
, Publisher's Note
, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations